Monascus pigment rubropunctatin derivative FZU-H reduces Aβ(1-42)-induced neurotoxicity in Neuro-2A cells

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by oxidative stress and amyloid-beta (Aβ) aggregation.
• Targeting Aβ-induced cellular injury presents a promising therapeutic strategy for AD.
• Previous research identified rubropunctatin derivative FZU-H from Monascus pigment with potential neuroprotective properties.

Purpose of the Study:

• To evaluate the neuroprotective efficacy of FZU-H against Aβ(1-42)-induced toxicity in Neuro-2A cells.
• To elucidate the underlying mechanisms of FZU-H's neuroprotective action.
• To assess FZU-H's impact on key Alzheimer's disease pathological markers.

Main Methods:

• Neuro-2A cells were treated with Aβ(1-42) and varying concentrations of FZU-H.
• Cell viability and toxicity assays were performed.
• Mechanisms investigated included caspase-3 activation, mitochondrial membrane potential, cellular redox balance, and Tau hyperphosphorylation induced by okadaic acid.

Main Results:

• FZU-H significantly diminished Aβ(1-42)-induced toxicity in Neuro-2A cells.
• FZU-H inhibited Aβ(1-42)-induced caspase-3 activation and mitochondrial membrane potential loss.
• FZU-H treatment attenuated Aβ(1-42)-induced redox imbalance and okadaic acid-induced Tau hyperphosphorylation.

Conclusions:

• FZU-H exhibits potent neuroprotective effects against key pathological features of Alzheimer's disease.
• The compound demonstrates therapeutic potential by mitigating Aβ toxicity and associated cellular damage.
• FZU-H represents a promising lead compound for further development in Alzheimer's disease treatment.